Table 3.
Top 10 research foci related to treatment in each 2-years period.
| Rank | 2012–2013 | 2014–2015 | 2016–2017 | 2018–2019 | 2020–2021 |
|---|---|---|---|---|---|
| 1 | Antibodies, monoclonal | Immunosuppressive agents | Infliximab | Gastrointestinal agents | Infliximab |
| 2 | Immunosuppressive agents | Infliximab | Gastrointestinal agents | Infliximab | Gastrointestinal agents |
| 3 | Infliximab | Antibodies, monoclonal | Immunosuppressive agents | Anti-inflammatory agents | Anti-inflammatory agents |
| 4 | Anti-inflammatory agents | Anti-inflammatory agents | Anti-inflammatory agents | Immunosuppressive agents | Remission induction |
| 5 | Anti-inflammatory agents, non-steroidal | Gastrointestinal agents | Remission induction | Remission induction | Tumor necrosis factor inhibitors |
| 6 | Antibodies, monoclonal, humanized | Anti-inflammatory agents, non-steroidal | Adalimumab | Antibodies, monoclonal, humanized | Immunosuppressive agents |
| 7 | Gastrointestinal agents | Remission induction | Colectomy | Adalimumab | Adalimumab |
| 8 | Remission induction | Antibodies, monoclonal, humanized | Antibodies, monoclonal | Colectomy | Antibodies, monoclonal, humanized |
| 9 | Postoperative complications | Adalimumab | Postoperative complications | Postoperative complications | Postoperative complications |
| 10 | Adalimumab | Colectomy | Antibodies, monoclonal, humanized | Antibodies, monoclonal | Colectomy |